The pharmaceutical industry isn’t happy about President Donald Trump’s trade war and is reportedly lobbying the President to slow down drug ...

Bearish flow noted in AbbVie (ABBV) with 8,035 puts trading, or 3x expected. Most active are 4/4 weekly 207.5 puts and 3/28 weekly 212.5 calls, ...

I'll start by comparing the revenue growth rates of AbbVie and Sanofi, then move on to discuss how often these two leaders in the autoimmune disease treatment market beat Wall Street analysts ...

What happens when biotech partners end up on opposite sides of a courtroom? That’s the question now looming over AbbVie and Genmab, two biotech heavyweights whose billion-dollar collaboration helped ...

Pharmaceutical giant AbbVie has filed a lawsuit against Genmab, claiming the Denmark-based drugmaker, who is also a commercial oncology partner with the North Chicago-based company, knowingly ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs. The new investment will grow its workforce at the site ...

Earlier this week, AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for the treatment of obesity, from Danish research ...

NEW YORK (Reuters) -Large deals involving pharmaceutical and biotech companies are stalling as executives grapple with ...